SynopsisTriciribine is a potent AKT inhibitor and a cell-permeable tricyclic nucleoside molecule with potential antineoplastic activity. The global Triciribine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a.....
SynopsisIpatasertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. The global Ipatasertib market was valued at US$ million in 2023 and is anticipated to reach US$ million .....
SynopsisIdelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). The global Idelalisib (CAL-101) market was valued at US$ million in 2023 and is anticipated to re.....
Synopsis2-Methyl-2-Pentenoic Acid is a carboxylic acid with the molecular formula C6H10O2, it is found in nature and has a sour, acidic, fruity, jammy, woody-like odour. The global 2-Methyl-2-Pentenoic Acid market was valued at US$ million in 2023 and is anticip.....
SynopsisBuparlisib is an orally bioavailable and selective pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor. The global Buparlisib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during t.....
SynopsisWortmannin is a potent, selective, cell-permeable and irreversible inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase)which also potently inhibits polo-like kinase 1. The global Wortmannin market was valued at US$ million in 2023 and is anticipated .....
SynopsisBerzosertib is an inhibitor of ataxia-telangiectasia mutated (ATM) Rad3-related protein kinase (ATR). The global Berzosertib (VE-822) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during .....
SynopsisSalubrinal is a selective Inhibitor of eIF2α dephosphorylation, inhibiting global protein translation. Salubrinal is a specific inhibitor of ER Stress induced apoptosis. The global Salubrinal market was valued at US$ million in 2023 and is anticipated to.....
SynopsisTolcapone is a reversible inhibitor of catechol-O-methyltransferase. The global Tolcapone market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030. North A.....
SynopsisLumiracoxib is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. The global Lumiracoxib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessi.....
